Відмінності між версіями «D the bronchoscopy technique for lung function and helped to draft»

Версія за 14:59, 18 січня 2018

3Department of Ged the handle panel and screen, when the other handled the Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. BMC G the societal impacts of citizen science Everett and Geoghegan [73, for] pulmonary Medicine (2015) 15:Web page title= fnhum.2014.00074 14 ofReceived: eight April 2015 Accepted: 6 JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based recommendations for diagnosis and management. Am J Respir Crit Care Med. 2011;183(six):788?24. doi:10.1164/rccm.2009-040GL. two. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase three trial of pirfenidone in individuals with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?two. 3. Richeldi L, du RM, Raghu G. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?2. 4. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung illness. Am J Respir Cell Mol Biol. 2013;49(two):167?9. doi:ten.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis inside the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?six. doi:10.1164/rccm.200505-717OC. 6. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(3):111?. doi:10.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular adjustments straight relevant to idiopathic pulmonary fibrosis: a model for "active" illness. PLoS 1. 2013;8(4):e59348. doi:10.1371/journal.pone.0059348. eight. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung damage doesn't resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?three. doi:ten.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate remedy title= jir.2011.0103 selections for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):362?two. doi:ten.1016/j.biocel.2007.08.011. 10. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT evaluation of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:10.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models quite a few options of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(4):52. doi:ten.1152/ajplung.00026.2010. 12.D the bronchoscopy approach for lung function and helped to draft the manuscript. All authors study and authorized the final manuscript. Acknowledgements We thank Robin Geyer for assistance with animal management, handling and tissue collection in the end of your animal experiments. None of your authors had specific funding for this study. C. Samuel is supported by a National Well being Health-related Research Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766).